Spark Therapeutics Inc., of Philadelphia, started enrolling a phase I/II trial with SPK-CHM for patients with choroideremia, an X-linked inherited retinal dystrophy which manifests in affected males in childhood as night blindness and a reduction of visual field, followed by progressive constriction of visual field, ultimately leading to complete blindness.